Chronic myelogenous leukemia (CML) is a type of cancer that has relatively positive prognosis. According to the National Cancer Institute, the overall 5-year survival rate of the patients with CML is 65.1%.
In the process of improving the 5-year survival rate, the creation of tyrosine kinase inhibitors contributes tremendously. In 2006, in the test to determine the effect of imatinib (Gleevec), the 5-year survival rate increased to 89%.
Besides, other new drugs are being developed, which is much likely to improve survival rates in the future.
Keywords: chronic myeloid leukemia prognosis; prognosis chronic myeloid leukemia